nitrendipine has been researched along with Cardiac Hypertrophy in 22 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The density of calcium channel binding sites as determined by [3H]-nitrendipine binding was found to be decreased in hearts of hyperthyroid rats but hardly altered by hypothyroidism." | 7.68 | Effect of hypo- and hyperthyroidism on binding of [3H]-nitrendipine to myocardial and brain membranes. ( Gross, G; Hanft, G; Kosinski, C, 1990) |
| "Recent studies indicate that cardiac and renal hypertrophy develop during desoxycorticosterone acetate (DOCA)-salt (DOC) treatment in hypertension-prone (SBH) and -resistant (SBN) rats, irrespective of systemic hemodynamic changes." | 7.67 | Nitrendipine prevents the development of cardiac hypertrophy in DOCA-salt-treated hypertension-prone (SBH) and -resistant (SBN) rats through nonhemodynamic mechanisms. ( Ben-Ishay, D; Eimerl, J; Kobrin, I; Mekler, J; Waksman, R, 1988) |
| "We designed experiments to determine whether intermittent hypoxia would produce significant pathologic and physiologic changes in rats and whether pretreatment with a calcium channel blocker, nitrendipine, would reduce the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia." | 7.67 | Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats. ( Buescher, P; de la Monte, SM; Farrukh, I; Gottlieb, J; Gurtner, G; Hutchins, GM; Kennedy, TP; Lodato, R; Michael, JR; Rock, PC, 1986) |
| "Nitrendipine (100 mg/kg) was given once daily at 10 AM or 10 PM for 16 weeks." | 5.30 | Administration time-dependent effect of nitrendipine on the reduction of cardiac hypertrophy in spontaneously hypertensive rats. ( Fujimura, A; Shiga, T; Sugimoto, K, 1999) |
| "A study was designed to clarify the effects of captopril (CAP) or nitrendipine (NITR) on cardiac hypertrophy and left ventricular expression of the laminin B2 or collagen (COL) gene in spontaneously hypertensive rats (SHRs)." | 3.68 | Effects of captopril or nitrendipine on left ventricular collagen or laminin B2 gene expression. ( Abe, M; Inaba, M; Ishii, J; Itabashi, A; Katayama, S, 1993) |
| "To evaluate the effect of nitrendipine on cardiac hypertrophy and inotropic response to isoproterenol in two-kidney, one-clip (2K,1C) renovascular hypertension, male Wistar rats (n = 56) were divided into a clipped group (K) (n = 28) and a sham group (S) (n = 28)." | 3.68 | Improvement of cardiac contractile response to beta-adrenergic stimulation in normal and two-kidney, one-clip hypertensive rats treated with nitrendipine. ( Fontan, M; Gallo, A; Gómez Llambi, H; Mazzadi, A; Taquini, CM, 1991) |
| "The density of calcium channel binding sites as determined by [3H]-nitrendipine binding was found to be decreased in hearts of hyperthyroid rats but hardly altered by hypothyroidism." | 3.68 | Effect of hypo- and hyperthyroidism on binding of [3H]-nitrendipine to myocardial and brain membranes. ( Gross, G; Hanft, G; Kosinski, C, 1990) |
| "Recent studies indicate that cardiac and renal hypertrophy develop during desoxycorticosterone acetate (DOCA)-salt (DOC) treatment in hypertension-prone (SBH) and -resistant (SBN) rats, irrespective of systemic hemodynamic changes." | 3.67 | Nitrendipine prevents the development of cardiac hypertrophy in DOCA-salt-treated hypertension-prone (SBH) and -resistant (SBN) rats through nonhemodynamic mechanisms. ( Ben-Ishay, D; Eimerl, J; Kobrin, I; Mekler, J; Waksman, R, 1988) |
| "We designed experiments to determine whether intermittent hypoxia would produce significant pathologic and physiologic changes in rats and whether pretreatment with a calcium channel blocker, nitrendipine, would reduce the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia." | 3.67 | Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats. ( Buescher, P; de la Monte, SM; Farrukh, I; Gottlieb, J; Gurtner, G; Hutchins, GM; Kennedy, TP; Lodato, R; Michael, JR; Rock, PC, 1986) |
| "In a double-blind study, 24 ESRD patients with LVH were randomized to 12 months' administration of either the angiotensin-converting enzyme (ACE) inhibitor perindopril (n = 14) or the calcium channel blocker nitrendipine (n = 10)." | 2.67 | Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade. ( Cuche, JL; Guerin, AP; London, GM; Marchais, SJ; Pannier, B; Safar, ME, 1994) |
| " Recent experimental data in spontaneously hypertensive rats indicate that the impaired coronary reserve can be significantly improved by the long-term administration of blood pressure lowering agents, e." | 2.37 | Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease. ( Strauer, BE, 1988) |
| "Nitrendipine (100 mg/kg) was given once daily at 10 AM or 10 PM for 16 weeks." | 1.30 | Administration time-dependent effect of nitrendipine on the reduction of cardiac hypertrophy in spontaneously hypertensive rats. ( Fujimura, A; Shiga, T; Sugimoto, K, 1999) |
| "Treatment with captopril, nitrendipine, or both reduced Gi alpha and increased guanylylimidodiphosphate-stimulated adenylyl cyclase activity in SHR." | 1.29 | Treatment in hypertensive cardiac hypertrophy, II. Postreceptor events. ( Böhm, M; Erdmann, E; Flesch, M; Gräbel, C; Knorr, A, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 12 (54.55) | 18.7374 |
| 1990's | 10 (45.45) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Böhm, M | 2 |
| Gräbel, C | 2 |
| Knorr, A | 2 |
| Erdmann, E | 2 |
| Flesch, M | 1 |
| London, GM | 1 |
| Pannier, B | 1 |
| Guerin, AP | 1 |
| Marchais, SJ | 1 |
| Safar, ME | 2 |
| Cuche, JL | 1 |
| Katayama, S | 1 |
| Abe, M | 1 |
| Inaba, M | 1 |
| Itabashi, A | 1 |
| Ishii, J | 1 |
| Shiga, T | 1 |
| Sugimoto, K | 1 |
| Fujimura, A | 1 |
| Taquini, CM | 1 |
| Gómez Llambi, H | 1 |
| Mazzadi, A | 1 |
| Fontan, M | 1 |
| Gallo, A | 1 |
| Muiesan, ML | 2 |
| Agabiti-Rosei, E | 2 |
| Romanelli, G | 2 |
| Beschi, M | 1 |
| Castellano, M | 1 |
| Alari, G | 1 |
| Rizzoni, D | 1 |
| Muiesan, G | 2 |
| Wang, LS | 1 |
| Bai, MY | 1 |
| Zhang, Z | 1 |
| Kosinski, C | 1 |
| Gross, G | 1 |
| Hanft, G | 1 |
| Sharma, RV | 1 |
| Butters, CA | 1 |
| Bhalla, RC | 1 |
| Mayoux, E | 1 |
| Callens, F | 1 |
| Swynghedauw, B | 1 |
| Charlemagne, D | 1 |
| Kobrin, I | 1 |
| Waksman, R | 1 |
| Mekler, J | 1 |
| Eimerl, J | 1 |
| Ben-Ishay, D | 1 |
| Strauer, BE | 2 |
| Vogt, M | 1 |
| Kreutz, KU | 1 |
| Motz, W | 1 |
| Nakanishi, H | 1 |
| Makino, N | 1 |
| Hata, T | 1 |
| Matsui, H | 1 |
| Yano, K | 1 |
| Yanaga, T | 1 |
| Weishaar, RE | 1 |
| Simpson, RU | 1 |
| Michael, JR | 1 |
| Kennedy, TP | 1 |
| Buescher, P | 1 |
| Farrukh, I | 1 |
| Lodato, R | 1 |
| Rock, PC | 1 |
| Gottlieb, J | 1 |
| Gurtner, G | 1 |
| de la Monte, SM | 1 |
| Hutchins, GM | 1 |
| Kazda, S | 1 |
| Kobayashi, K | 1 |
| Tarazi, RC | 1 |
| Geri, A | 1 |
| Montani, G | 1 |
| Bouthier, JD | 1 |
| De Luca, N | 1 |
| Simon, AC | 1 |
1 review available for nitrendipine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Regression of myocardial and coronary vascular hypertrophy in hypertensive heart disease.
Topics: Cardiomegaly; Heart Diseases; Humans; Hypertension; Nitrendipine | 1988 |
2 trials available for nitrendipine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Cardiac hypertrophy, aortic compliance, peripheral resistance, and wave reflection in end-stage renal disease. Comparative effects of ACE inhibition and calcium channel blockade.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aorta; Calcium Channel Blockers; Cardiomegaly; Compliance; | 1994 |
Comparison of the effects of nitrendipine and captopril on the regression of hypertensive left ventricular hypertrophy.
Topics: Adult; Aged; Captopril; Cardiomegaly; Female; Humans; Hypertension; Male; Middle Aged; Nitrendipine; | 1991 |
19 other studies available for nitrendipine and Cardiac Hypertrophy
| Article | Year |
|---|---|
Treatment in hypertensive cardiac hypertrophy, I. Neuropeptide Y and beta-adrenoceptors.
Topics: Adenylyl Cyclases; Animals; Captopril; Cardiomegaly; Hypertension; Male; Myocardium; Neuropeptide Y; | 1995 |
Treatment in hypertensive cardiac hypertrophy, II. Postreceptor events.
Topics: Adenosine Diphosphate Ribose; Adenylyl Cyclases; Animals; Captopril; Cardiomegaly; GTP-Binding Prote | 1995 |
Effects of captopril or nitrendipine on left ventricular collagen or laminin B2 gene expression.
Topics: Animals; Captopril; Cardiomegaly; Collagen; Extracellular Matrix; Gene Expression; Heart; Heart Vent | 1993 |
Administration time-dependent effect of nitrendipine on the reduction of cardiac hypertrophy in spontaneously hypertensive rats.
Topics: Animals; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Circadian Rhythm; Drug Administrati | 1999 |
Improvement of cardiac contractile response to beta-adrenergic stimulation in normal and two-kidney, one-clip hypertensive rats treated with nitrendipine.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Heart; Hypertension, Renal; Isoproterenol; Male; | 1991 |
Improved left ventricular systolic and diastolic function after regression of cardiac hypertrophy, treatment withdrawal, and redevelopment of hypertension.
Topics: Adult; Captopril; Cardiomegaly; Echocardiography; Exercise; Hemodynamics; Humans; Hypertension; Midd | 1991 |
[Effects of nitrendipine on diastolic left ventricular function and hypertrophy in patients with hypertension].
Topics: Adult; Cardiomegaly; Diastole; Echocardiography, Doppler; Female; Humans; Hypertension; Male; Middle | 1990 |
Effect of hypo- and hyperthyroidism on binding of [3H]-nitrendipine to myocardial and brain membranes.
Topics: Animals; Brain; Calcium Channels; Cardiomegaly; Hyperthyroidism; Hypothyroidism; In Vitro Techniques | 1990 |
Alterations in the plasma membrane properties of the myocardium of spontaneously hypertensive rats.
Topics: Adenosine Triphosphatases; Animals; Cardiomegaly; Cell Membrane; Ion Channels; Male; Myocardium; Nif | 1986 |
Adaptational process of the cardiac Ca2+ channels to pressure overload: biochemical and physiological properties of the dihydropyridine receptors in normal and hypertrophied rat hearts.
Topics: Adaptation, Physiological; Animals; Binding, Competitive; Calcium Channel Blockers; Calcium Channels | 1988 |
Nitrendipine prevents the development of cardiac hypertrophy in DOCA-salt-treated hypertension-prone (SBH) and -resistant (SBN) rats through nonhemodynamic mechanisms.
Topics: Animals; Blood Pressure; Cardiomegaly; Desoxycorticosterone; Drug Resistance; Hemodynamics; Hyperten | 1988 |
[Regression of hypertrophy following nitrendipine: effect on systolic and diastolic function].
Topics: Adult; Blood Pressure; Cardiac Volume; Cardiomegaly; Diastole; Echocardiography; Female; Follow-Up S | 1989 |
Sarcolemmal Ca2+ transport activities in cardiac hypertrophy caused by pressure overload.
Topics: Animals; Aorta, Abdominal; Blood Pressure; Ca(2+) Mg(2+)-ATPase; Calcium; Calcium Channels; Calcium- | 1989 |
Involvement of vitamin D3 with cardiovascular function. II. Direct and indirect effects.
Topics: Animals; Aorta; Calcitriol; Calcium; Cardiomegaly; Cholecalciferol; Hydroxycholecalciferols; Ions; M | 1987 |
Nitrendipine attenuates the pulmonary vascular remodeling and right ventricular hypertrophy caused by intermittent hypoxia in rats.
Topics: Animals; Cardiomegaly; Heart Ventricles; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Male; Muscle | 1986 |
Effects of nitrendipine on vascular integrity.
Topics: Animals; Blood Pressure; Cardiomegaly; Cerebrovascular Disorders; Female; Hypertension; Nitrendipine | 1986 |
The chronic effect of nitrendipine on heart and regional blood flow in renovascular hypertensive rats.
Topics: Animals; Blood Pressure; Cardiac Output; Cardiomegaly; Cerebrovascular Circulation; Coronary Circula | 1987 |
Relation between cardiac hypertrophy and forearm vascular structural changes before and during long-term antihypertensive treatment.
Topics: Adult; Antihypertensive Agents; Blood Pressure; Captopril; Cardiomegaly; Female; Forearm; Humans; Hy | 1988 |
Cardiac hypertrophy and arterial distensibility in essential hypertension.
Topics: Adult; Aged; Arteries; Blood Flow Velocity; Cardiomegaly; Humans; Hypertension; Middle Aged; Nifedip | 1985 |